High-grade B-cell lymphoma: how to diagnose and treat

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Boerma EG, Siebert R, Kluin PM, et al. Translocations involv- ing 8q24 in Burkitt lymphoma and other malignant lympho- mas: a historical review of cytogenetics in the light of todays knowledge. Leukemia. 2009;23:225–234.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Oki Y, Westin JR, et al. A clinician’s guide to dou- ble hit lymphomas. Br J Haematol. 2015;168:784–795.
   PubMed Web of Science ®Google Scholar
• Thangavelu M, Olopade O, Beckman E, et al. Clinical, mor- phologic, and cytogenetic characteristics of patients with lym- phoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990;2:147–158.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–2279.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35(20):2260–2267.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Nasta SD, Svoboda J, et al. ‘Double-hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol. 2014;166(3):369–374.
   PubMed Web of Science ®Google Scholar
• Moore EM, Aggarwal N, Surti U, et al. Further exploration of the complexities of large B-cell lymphomas with MYC abnormalities and the importance of a blastoid morphology. Am J Surg Pathol. 2017;41(9):1155–1166.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, et al. A new immu- nostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Hong J, Park S, Park J, et al. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 2011;52:1904–1912.
   PubMed Web of Science ®Google Scholar
• Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol. 2009;22:1094–1101.
   PubMed Web of Science ®Google Scholar
• Sjo LD, Poulsen CB, Hansen M, et al. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol. 2007;79:501–507.
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214–1217.
   PubMed Web of Science ®Google Scholar
• Karube K, Campo E. MYC alterations in diffuse large B-cell lymphomas. Semin Hematol. 2015;52(2):97–106.
   PubMed Web of Science ®Google Scholar
• Obermann EC, Csato M, Dirnhofer S, et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol. 2009;62(8):754–756.
   PubMed Web of Science ®Google Scholar
• Ye Q, Xu-Monette ZY, Tzankov A, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016;7(3):2401–16. 4. 4.
   PubMed Web of Science ®Google Scholar
• Pedersen MO, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42–48.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Cuilliere-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466–2474.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–3365.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–3459.
   PubMed Web of Science ®Google Scholar
• Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long- distance polymerase chain reaction-based assays. Cancer Res. 2000;60:2335–2341.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Mecucci C, Stul M, et al. Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non-Hodgkin’s lymphomas with BCL6/LAZ3 rearrangement. Genes Chromosomes Cancer. 1995;14:1–7.
   PubMed Web of Science ®Google Scholar
• Ohno H, Fukuhara S. Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. Leuk Lymphoma. 1997;27:53–63.
   PubMed Web of Science ®Google Scholar
• Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007;21(3):515–523.
   PubMed Web of Science ®Google Scholar
• Pedersen MO, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma: a single centre’s experience. Eur J Haematol. 2012;89(1):63–71.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Kreuz M, Kohler CW, et al. Molecular mechanisms in malignant lymphomas network project. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–735.
   PubMed Web of Science ®Google Scholar
• Foot NJ, Dunn RG, Geoghegan H, et al. Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin’s lymphoma: a single centre’s experience. J Clin Pathol. 2011;64(9):802–808.
   PubMed Web of Science ®Google Scholar
• Cummings CA, Peters E, Lacroix L. The role of next-generation sequencing in enabling personalized oncology therapy. Clin Transl Sci. 2016;9:283–292.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20:728–740.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181–185.
   PubMed Web of Science ®Google Scholar
• Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23:677–692.
   PubMed Web of Science ®Google Scholar
• Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21:1199–1208.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–195.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly PJ, Mareschal S, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22:2919–2928.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–1407.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–690.
   PubMed Web of Science ®Google Scholar
• Evrard SM, Péricart S, Grand D, et al. Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Haematologica. 2018;104: e154-e157.
   PubMedGoogle Scholar
• Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335–1342.
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891–901.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23:777–783.
   PubMed Web of Science ®Google Scholar
• McPhail ED, Maurer MJ, Macon WR, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018;103:1899-1907.
   Web of Science ®Google Scholar
• Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935–943.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH–BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34:327–340.
   PubMed Web of Science ®Google Scholar
• Sun H, Savage KJ, Karsan A, et al. Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15:341–348.
   PubMed Web of Science ®Google Scholar
• Lin P, Medeiros LJ. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007;92(10):1297–1301.
   PubMed Web of Science ®Google Scholar
• Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25–33.
   PubMed Web of Science ®Google Scholar
• Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH/BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145–156.
   PubMed Web of Science ®Google Scholar
• Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118(17):4173–4183.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Geyer SM, Lozanski G, et al. Complete response to induction therapy in patients with MYC-positive and double-hit non- Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677–1685.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang L, Wang Y, et al. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review. Int J Clin Exp Pathol. 2013;6(4):788–794.
   PubMed Web of Science ®Google Scholar
• McPhail ED, Maurer MJ, Macon WR, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018;103:1899–1907. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29(12):1652–1660.
   PubMed Web of Science ®Google Scholar
• Clipson A, Barrans S, Zeng N, et al. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res. 2015;1(3):125–133.
   PubMedGoogle Scholar
• Pillai RK, Sathanoori M, Van Oss SB, et al. Double-hit B- cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B- cell lymphomas. Am J Surg Pathol. 2013;37(3):323–332.
   PubMed Web of Science ®Google Scholar
• Li S, Desai P, Lin P, et al. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology. 2016;68(7):1090–1098.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Zwick C, Zeynalova S, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin’s lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2008 Mar;19(3):545–552. Epub 2007 Dec 6.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Tsui A, Wall M, et al. Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol. 2016;7(1):52–64.
   PubMed Web of Science ®Google Scholar
• Hancock C, Knouse P, Almanaseer I, et al. A retrospective study of double hit lymphomas in elderly patients (aged > 70 years): overall outcomes. Clin Lymph Myel Leuk. 2018;18(4):280–285.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Fanale AM, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study”. Lancet Haematol. 2018;5(12):e609–e617.
   PubMed Web of Science ®Google Scholar
• Sorror M, Maris M, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Villa D, Sehn L. Double hit lymphoma: do we need a ‘double hit’ of intensive therapy? Leuk Lymphoma. 2018;59(8):1767–1768.
   PubMed Web of Science ®Google Scholar
• Mason K, Vandenberg C, Scott C, et al. In vivo efficacy of the BCL-2 antagonist ABT-737 against aggressive Mycdriven lymphomas. Proc Natl Acad Sci U S A. 2008;105:17961–17966.
   PubMed Web of Science ®Google Scholar
• Vandenberg C, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013;121:2285–2288.
   PubMed Web of Science ®Google Scholar
• Johnson-Farley N, Veliz J, Bhagavathi S, et al. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells. Leuk Lymphoma. 2015;56:2146–2152.
   PubMed Web of Science ®Google Scholar
• Davids M, Seymour J, Gerecitano J, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol. 2014;(Meeting Abstracts) 32(Suppl. 5s):abstract 8522.
   Google Scholar
• Delmore J, Issa G, Lemieux M, et al. Bet bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–917.
   PubMed Web of Science ®Google Scholar
• Takimoto-Shimomura T, Tsukamoto T, Maegawa S, et al. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs. DOI:10.1007/s10637-018-0623-8
   Web of Science ®Google Scholar
• Kochenderfer J, Dudley M, Kassim S, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–549.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of Germinal Center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2018;37:190–201.
   PubMed Web of Science ®Google Scholar